#Baricitinib plus #Remdesivir for Hospitalized Adults with #Covid-19

Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) … Continue reading #Baricitinib plus #Remdesivir for Hospitalized Adults with #Covid-19